Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
S. A. Mostafa; R. L. Coleman; O. F. Agbaje; A. M. Gray; R. R. Holman; M. A. Bethel
Author Information: Diabetes Trials Unit
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.